Royal DSM has reported the completion of Kensey Nash acquisition by merging its subsidiary Biomedical Acquisition with and into Kensey Nash. With this acquisition, Kensey Nash has now become DSM’s indirect wholly-owned subsidiary.
Kensey Nash is a biomedical company based in the United States, focusing on regenerative medicine using its proprietary synthetic and collagen polymer technology. The company produces and markets medical device components in general surgery, spinal, sports medicine, orthopedic and cardiology. Its products, such as extracellular matrix, bone mineral, synthetic polymer, collagen processing and mechanical device, lay the cornerstone to develop a wide range of advancements in regenerative medicine.
Through this merger, DSM can now reinforce its emerging biomedical business, DSM Biomedical, and fulfill its strategic and financial criteria. This acquisition will help DSM Biomedical to realize its strategic goal of strengthening its footprint in bio-interactive, bio-active and bio-passive materials. DSM can now extend its presence in the bio-passive (medical polymers and coatings) market and as well as in the emerging bio-active (drug delivery and resorbable polymers) materials market. The merger also provides the company a pipeline of advanced technologies in the emerging tissue engineering and regenerative medicine (bio-interactive materials) field.
DSM’s existing portfolio can now leverage Kensey Nash’s strong network and customer base in the United States. Moreover, Kensey Nash’s product portfolio will find huge market opportunities thanks to DSM’s strong customer base in Asia and Europe. An integration team comprising representatives from both companies will work on the complete integration of the two organizations. The Kensey Nash acquisition will help meet DSM’s objective of achieving sales of €1 billion by 2020 and will establish DSM Biomedical as a lucrative growth platform.